- Home
- YI vs IFRX Comparison
YI vs IFRX Comparison
Compare YI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- IFRX
- Stock Information
- Founded
- YI 2010
- IFRX 2007
- Country
- YI China
- IFRX Germany
- Employees
- YI N/A
- IFRX N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- IFRX Health Care
- Exchange
- YI Nasdaq
- IFRX Nasdaq
- Market Cap
- YI 70.0M
- IFRX 65.8M
- IPO Year
- YI N/A
- IFRX 2017
- Fundamental
- Price
- YI $7.09
- IFRX $0.81
- Analyst Decision
- YI
- IFRX Strong Buy
- Analyst Count
- YI 0
- IFRX 4
- Target Price
- YI N/A
- IFRX $7.75
- AVG Volume (30 Days)
- YI 11.9K
- IFRX 328.2K
- Earning Date
- YI 06-19-2025
- IFRX 08-07-2025
- Dividend Yield
- YI N/A
- IFRX N/A
- EPS Growth
- YI N/A
- IFRX N/A
- EPS
- YI N/A
- IFRX N/A
- Revenue
- YI $1,984,717,013.00
- IFRX $140,242.00
- Revenue This Year
- YI N/A
- IFRX N/A
- Revenue Next Year
- YI N/A
- IFRX $6,309.47
- P/E Ratio
- YI N/A
- IFRX N/A
- Revenue Growth
- YI N/A
- IFRX 30.90
- 52 Week Low
- YI $4.15
- IFRX $0.71
- 52 Week High
- YI $12.90
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- YI 37.32
- IFRX 37.96
- Support Level
- YI $6.65
- IFRX $0.78
- Resistance Level
- YI $7.80
- IFRX $0.83
- Average True Range (ATR)
- YI 0.43
- IFRX 0.04
- MACD
- YI -0.11
- IFRX 0.02
- Stochastic Oscillator
- YI 21.32
- IFRX 60.00
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.